183 related articles for article (PubMed ID: 16410782)
1. Circulating tyrosinase and MART-1 mRNA does not independently predict relapse or survival in patients with AJCC stage I-II melanoma.
Schmidt H; Sorensen BS; Sjoegren P; Christensen IJ; Fode K; Larsen J; Nexo E; von der Maase H
J Invest Dermatol; 2006 Apr; 126(4):849-54. PubMed ID: 16410782
[TBL] [Abstract][Full Text] [Related]
2. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
3. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
4. Molecular Staging of Sentinel Lymph Nodes Identifies Melanoma Patients at Increased Risk of Nodal Recurrence.
Kimbrough CW; Egger ME; McMasters KM; Stromberg AJ; Martin RC; Philips P; Scoggins CR
J Am Coll Surg; 2016 Apr; 222(4):357-63. PubMed ID: 26875070
[TBL] [Abstract][Full Text] [Related]
5. Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy.
Schmidt H; Sorensen BS; Fode K; Nexo E; von der Maase H
Melanoma Res; 2005 Oct; 15(5):409-16. PubMed ID: 16179868
[TBL] [Abstract][Full Text] [Related]
6. MART-1/Melan-A and tyrosinase transcripts in peripheral blood of melanoma patients: PCR analyses and follow-up testing in relation to clinical stage and disease progression.
Strohal R; Mosser R; Kittler H; Wolff K; Jansen B; Brna C; Stingl G; Pehamberger H
Melanoma Res; 2001 Oct; 11(5):543-8. PubMed ID: 11595894
[TBL] [Abstract][Full Text] [Related]
7. Lack of prognostic importance of reverse-transcriptase polymerase chain reaction detection of circulating messenger RNA in patients with melanoma.
Ranieri JM; Wagner JD; Wiebke EA; Azuaje R; Smith ML; Wenck S; Daggy J; Coleman JJ
Plast Reconstr Surg; 2005 Apr; 115(4):1058-63. PubMed ID: 15793446
[TBL] [Abstract][Full Text] [Related]
8. Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma.
Schittek B; Bodingbauer Y; Ellwanger U; Blaheta HJ; Garbe C
Br J Dermatol; 1999 Jul; 141(1):30-6. PubMed ID: 10417512
[TBL] [Abstract][Full Text] [Related]
9. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases.
Curry BJ; Myers K; Hersey P
J Clin Oncol; 1999 Aug; 17(8):2562-71. PubMed ID: 10561323
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma.
Visús C; Andres R; Mayordomo JI; Martinez-Lorenzo MJ; Murillo L; Sáez-Gutiérrez B; Diestre C; Marcos I; Astier P; Godino J; Carapeto-Marquez de Prado FJ; Larrad L; Tres A
Melanoma Res; 2007 Apr; 17(2):83-9. PubMed ID: 17496783
[TBL] [Abstract][Full Text] [Related]
11. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group.
Palmieri G; Strazzullo M; Ascierto PA; Satriano SM; Daponte A; Castello G
J Clin Oncol; 1999 Jan; 17(1):304-11. PubMed ID: 10458247
[TBL] [Abstract][Full Text] [Related]
12. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
Koyanagi K; O'Day SJ; Gonzalez R; Lewis K; Robinson WA; Amatruda TT; Wang HJ; Elashoff RM; Takeuchi H; Umetani N; Hoon DS
J Clin Oncol; 2005 Nov; 23(31):8057-64. PubMed ID: 16258104
[TBL] [Abstract][Full Text] [Related]
13. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR.
de Vries TJ; Fourkour A; Punt CJ; van de Locht LT; Wobbes T; van den Bosch S; de Rooij MJ; Mensink EJ; Ruiter DJ; van Muijen GN
Br J Cancer; 1999 May; 80(5-6):883-91. PubMed ID: 10360670
[TBL] [Abstract][Full Text] [Related]
14. Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine.
Wascher RA; Morton DL; Kuo C; Elashoff RM; Wang HJ; Gerami M; Hoon DS
J Clin Oncol; 2003 Jul; 21(13):2558-63. PubMed ID: 12829676
[TBL] [Abstract][Full Text] [Related]
15. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors.
Proebstle TM; Jiang W; Högel J; Keilholz U; Weber L; Voit C
Br J Cancer; 2000 Jan; 82(1):118-23. PubMed ID: 10638977
[TBL] [Abstract][Full Text] [Related]
16. The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival.
Aubin F; Chtourou M; Teyssier JR; Laubriet A; Mougin CH; Blanc D; Humbert P
Melanoma Res; 2000 Apr; 10(2):113-8. PubMed ID: 10803711
[TBL] [Abstract][Full Text] [Related]
17. Molecular staging of the sentinel lymph node in melanoma patients: correlation with clinical outcome.
Romanini A; Manca G; Pellegrino D; Murr R; Sarti S; Bianchi F; Alsharif A; Orlandini C; Zucchi V; Castagna M; Gandini D; Salimbeni G; Ghiara F; Barachini P; Mariani G
Ann Oncol; 2005 Nov; 16(11):1832-40. PubMed ID: 16107497
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma.
Schuster R; Bechrakis NE; Stroux A; Busse A; Schmittel A; Scheibenbogen C; Thiel E; Foerster MH; Keilholz U
Clin Cancer Res; 2007 Feb; 13(4):1171-8. PubMed ID: 17317826
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction.
Palmieri G; Ascierto PA; Perrone F; Satriano SM; Ottaiano A; Daponte A; Napolitano M; Caracò C; Mozzillo N; Melucci MT; Cossu A; Tanda F; Gallo C; Satriano RA; Castello G
J Clin Oncol; 2003 Mar; 21(5):767-73. PubMed ID: 12610172
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the use of tyrosinase-specific and melanA/MART-1-specific reverse transcriptase-coupled--polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma.
Brownbridge GG; Gold J; Edward M; MacKie RM
Br J Dermatol; 2001 Feb; 144(2):279-87. PubMed ID: 11251559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
